Sugi Predict

Sugi Predict / Compounds / SCHEMBL142891

SCHEMBL142891

SCHEMBL142891

CNc1nc2c(N(Cc3ccccc3)Cc3ccccc3)nc3ccccc3c2n1CC(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR7 Q9NYK1 9/20 0.38
▸ LMNA P02545 4/20 0.38
▸ POLB P06746 1/20 0.38
▸ HRH2 P25021 1/20 0.38
▸ ADRA1D P25100 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ ADORA2A P29274 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ NUDT1 P36639 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ TLR8 Q9NR97 1/20 0.38
▸ CASP1 P29466 2/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ HTT P42858 1/20 0.35
▸ CASP7 P55210 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31092876 1.00 TLR7 (0.38) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL4620764 0.93 TLR7 (0.34) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL12245200 0.88 APP (0.42) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL146701 0.86 TLR7 (0.44) TLR7POLBTLR8
SCHEMBL4979244 0.84 TLR7 (0.45) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL12245253 0.84 TLR7 (0.40) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL12296518 0.84 TLR7 (0.41) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL30448090 0.83 TLR7 (0.39) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL143565 0.83 TLR7 (0.39) TLR7LMNAPOLBHRH2ADRA1D
SCHEMBL4207212 0.81 MEN1 (0.46) TLR7LMNAPOLBSMN1; SMN2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096103-A1 IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2013-04-18 — — US claimed
US-20110217323-A1 IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2011-09-08 — — US claimed
US-20080213308-A1 Imidazoquinoline Compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-09-04 — — US claimed
EP-4585610-A2 MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS Seqirus UK Limited (GB) 2025-07-16 — — EP disclosed
EP-4144368-B1 RSV IMMUNIZATION REGIMEN GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-02-26 — — EP disclosed
EP-3527224-B1 RSV IMMUNIZATION REGIMEN GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-02-26 — — EP disclosed
US-20250042951-A1 PRE-FUSION RSV F ANTIGENS NOVARTIS AG (CH) 2025-02-06 — — US disclosed
US-12139512-B2 Pre-fusion RSV F antigens GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-11-12 — — US disclosed
US-20240299527-A1 RSV IMMUNIZATION REGIMEN NOVARTIS AG (CH) 2024-09-12 — — US disclosed
US-20240299537-A1 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE SEQIRUS UK LTD (GB) 2024-09-12 — — US disclosed
US-20240239845-A1 PRE-FUSION RSV F ANTIGENS NOVARTIS AG (CH) 2024-07-18 — — US disclosed
WO-2007052056-A1 ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 — — WO disclosed
WO-2007052055-A1 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 — — WO disclosed
WO-2007052155-A2 INFLUENZA VACCINE WITH REDUCED AMOUNT OF OIL-IN-WATER EMULSION AS ADJUVANT NOVARTIS VACCINES AND DIAGNOSTICS SRL (IT) 2007-05-10 — — WO disclosed
WO-2007041432-A2 CROSS-NEUTRALIZATION OF HCV WITH RECOMBINANT PROTEINS NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-04-12 — — WO disclosed
WO-2007011777-A2 SMALL ANIMAL MODEL FOR HCV REPLICATION NOVARTIS AG (CH) 2007-01-25 — — WO disclosed
WO-2006091517-A2 IMMUNOGENS FROM UROPATHOGENIC ESCHERICHIA COLI NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-08-31 — — WO disclosed
WO-2006089264-A2 PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-08-24 — — WO disclosed
WO-2006064378-A2 ADJUVANT ACTIVITY OF GASTROINTESTINAL PEPTIDES DE MAGISTRIS MARIA TERESA (IT) 2006-06-22 — — WO disclosed
WO-2006031878-A2 IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) 2006-03-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042951-A1 PRE-FUSION RSV F ANTIGENS FURIN, CD69, LY96 TLR7 485/4885LMNA 480/4885POLB 3894/4885
US-12139512-B2 Pre-fusion RSV F antigens FURIN, CD69, LY96 TLR7 485/4885LMNA 480/4885POLB 3894/4885
US-20130096103-A1 IMIDAZOQUINOLINE COMPOUNDS IFNG, IRF3, MYD88 TLR7 13/4885LMNA 4398/4885POLB 2702/4885
US-20240299527-A1 RSV IMMUNIZATION REGIMEN IL5, IL15, IFNG TLR7 48/4885LMNA 4368/4885POLB 1481/4885
US-20110217323-A1 IMIDAZOQUINOLINE COMPOUNDS IFNG, IRF3, MYD88 TLR7 13/4885LMNA 4398/4885POLB 2702/4885
US-20240239845-A1 PRE-FUSION RSV F ANTIGENS FURIN, CD69, LY96 TLR7 485/4885LMNA 480/4885POLB 3894/4885
US-20240299537-A1 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE LY96, PHOSPHO1, ASGR1 TLR7 73/4885LMNA 2986/4885POLB 1062/4885
US-20080213308-A1 Imidazoquinoline Compounds IFNG, IRF3, MYD88 TLR7 13/4885LMNA 4398/4885POLB 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.